News23/06/2025
Libertas Bio licenses gusacitinib to Sanofi
Formation Bio, Inc. →Formation Bio announced that its subsidiary Libertas Bio licensed the oral dual JAK/SYK inhibitor gusacitinib to Sanofi. Sanofi planned a Phase 1 study in a new indication. Potential upfront and milestone payments could reach [figure hidden], with low- to mid-teen royalties on future sales. These are contingent subsidiary transaction economics, not realized parent revenue. Gusacitinib had been acquired from Asana BioSciences in 2022 as part of a wider investigational portfolio. The announcement illustrates the parent’s acquire-develop-partner model while keeping the licensing subsidiary distinct.